| Pharmaceutical Information |
| Drug Name |
Deucravacitinib |
| Drug ID |
BADD_D02549 |
| Description |
Deucravacitinib is under investigation in clinical trial NCT04772079 (A Study to Evaluate the Drug Levels, Efficacy and Safety of BMS-986165 in Adolescent Participants With Moderate to Severe Plaque Psoriasis). |
| Indications and Usage |
Not Available |
| Marketing Status |
investigational |
| ATC Code |
L04AA56 |
| DrugBank ID |
DB16650
|
| KEGG ID |
D11817
|
| MeSH ID |
C000628674
|
| PubChem ID |
134821691
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
0003-0895; 50193-4323; 63285-893 |
| UNII |
N0A21N6RAU
|
| Synonyms |
deucravacitinib | BMS-986165 |
|
| Chemical Information |
| Molecular Formula |
C20H22N8O3 |
| CAS Registry Number |
1609392-27-9 |
| SMILES |
CNC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
